ProteoNic and ORYZON awarded European grant for joint development of therapeutic antibodies against prostate cancer
21-Sep-2010 -
ProteoNic and ORYZON genomics have joined forces to develop new antibodies against prostate cancer and generate cost-effective production-ready cell lines. ProteoNic will use its expression expertise and UNic™ toolbox production yield enhancer to optimize the potential of ORYZON’s proprietary ...
antibodies
cell lines
genomics
+4